Repligen (RGEN) Projected to Post Earnings on Tuesday

Repligen (NASDAQ:RGEN) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, April 29th. Analysts expect Repligen to post earnings of $0.35 per share and revenue of $163.65 million for the quarter. Repligen has set its FY 2025 guidance at 1.670-1.760 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect Repligen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $144.75 on Friday. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The stock has a market capitalization of $8.13 billion, a price-to-earnings ratio of -283.82, a PEG ratio of 4.54 and a beta of 1.27. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business has a 50-day moving average of $139.80 and a 200-day moving average of $145.86.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on RGEN. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Thursday, April 17th. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group dropped their target price on shares of Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a report on Wednesday, April 16th. Finally, Royal Bank of Canada lifted their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $176.82.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.